11:31 AM EST - The Yield Growth Corp. : Announced that its majority owned subsidiary NeonMind, on June 3, 2020 filed a U.S. provisional patent application in the United States for the invention relating to therapeutic administration of psilocybin or psilocin combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues. The provisional patent is for a proposed guided psychedelic psilocybin therapy protocol using psychotherapy prior to, during and after the psychoactive effects of the Psilocybin are felt by the patient. The psychedelic assisted psychotherapy is designed to assist in gaining insights from positive psychedelic experiences, to be integrated into everyday life and to help plan, prepare and make sense of psychedelic experiences for a therapeutic result. It can include an exploration of unresolved issues in the patient's life that are embedded in his or her subconscious, including discussions or examinations of pain. It may also include building self-esteem, the patient taking responsibility for his or her own condition, self empowerment, and acknowledging or releasing any unhealthy self defence mechanism of overeating. The Yield Growth Corp.
shares BOSS:CNX are trading off 10 percent at $0.14.
